Ocular toxicity from systemically administered xenobiotics

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 10, 2012, Pages 1277-1291

  Gokulgandhi, Mitan R ^a   Vadlapudi, Aswani Dutt ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Corneal toxicities; Ocular complications; Optic neuropathy; Retinopathy; Xenobiotics

Indexed keywords

AMANTADINE; AMIODARONE; AUROTHIOMALATE; CARBOPLATIN; CETIRIZINE; CHLORPROMAZINE; CLOFAZIMINE; COLLOIDAL GOLD; CORTICOSTEROID; CYTARABINE; DIGOXIN; ERLOTINIB; ETHAMBUTOL; GEFITINIB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; ISOTRETINOIN; LINEZOLID; NITROFURANTOIN; PHENOTHIAZINE; RIFABUTIN; ROFECOXIB; SUNITINIB; TAMOXIFEN; TOPIRAMATE; UNINDEXED DRUG; VANDETANIB; VIGABATRIN; XENOBIOTIC AGENT;

ACNE; ACUTE GRANULOCYTIC LEUKEMIA; ANTERIOR EYE SEGMENT; ANXIETY DISORDER; ATYPICAL MYCOBACTERIOSIS; BLEPHAROCONJUNCTIVITIS; BLOOD RETINA BARRIER; BLURRED VISION; BRAIN PSEUDOTUMOR; BREAST CANCER; CENTRAL SCOTOMA; CHOROID DISEASE; CHRONIC URTICARIA; CHRYSIASIS; CLOSED ANGLE GLAUCOMA; COLOR VISION DEFECT; CONGESTIVE HEART FAILURE; CONJUNCTIVA DISCOLORATION; CONJUNCTIVAL DEPOSIT; CONJUNCTIVAL HYPEREMIA; CONJUNCTIVITIS; CONTACT LENS; CORNEA DISCOLORATION; CORNEA DISEASE; CORNEA EDEMA; CORNEA ENDOTHELIAL DYSFUNCTION; CORNEA EPITHELIUM; CORNEA NEOVASCULARIZATION; CORNEA OPACITY; CORNEA REFLEX; CORNEA STEEPENING; CORNEA STROMA; CORNEA ULCER; CORNEAL EPITHELIAL CYST; CRYSTALLINE KERATOPATHY; DEPRESSION; DIPLOPIA; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG MONITORING; DRUG WITHDRAWAL; DRY EYE; EPILEPSY; EXOPHTHALMOS; EYE COLOR; EYE DISCOMFORT; EYE DISEASE; EYE EXAMINATION; EYE INFLAMMATION; EYE IRRITATION; EYE TOXICITY; EYELID DISEASE; EYELID EDEMA; FABRY DISEASE; GLIOBLASTOMA; GRAM POSITIVE INFECTION; HAY FEVER; HEAD AND NECK CANCER; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOPYON; INFLAMMATION; IRIDOCYCLITIS; KERATITIS; KERATOCONJUNCTIVITIS; KERATOCONJUNCTIVITIS SICCA; KERATOPATHY; KIDNEY CARCINOMA; LEPROSY; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALARIA; MASSIVE CHOROIDAL EFFUSION; METASTASIS; MIGRAINE; MYDRIASIS; MYOPIA; NEUROOPHTHALMOLOGY; NIGHT BLINDNESS; NIGHT VISION; NONHUMAN; OCULOGYRIC CRISIS; OPTIC DISK ANOMALY; OPTIC NERVE DISEASE; OPTIC NEURITIS; ORBIT DISEASE; OVARY CARCINOMA; PAPILLEDEMA; PARKINSON DISEASE; PERENNIAL RHINITIS; PERIORBITAL RASH; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; PIGMENT EPITHELIUM; PIGMENTATION; POSTERIOR EYE SEGMENT; PSORIASIS; PUPIL; PYODERMA GANGRENOSUM; RASH; RETINA DETACHMENT; RETINA DISEASE; RETINA EDEMA; RETINA MACULOPATHY; RETINITIS; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SCAR FORMATION; SIDE EFFECT; SLIT LAMP; SOLID TUMOR; SUBCAPSULAR CATARACT; SYSTEMIC LUPUS ERYTHEMATOSUS; TEAR OSMOLARITY; TORTUOUS EYELASH; TREMOR; TRICHOMEGALY; TUBERCULOSIS; URINARY TRACT INFECTION; UVEITIS; VISION; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT; VISUAL SYSTEM PARAMETERS; WHORL KERATOPATHY; XANTHOPSIA;

EYE; HUMANS; MELANINS; OPTIC NERVE; OPTIC NERVE DISEASES; RETINA; VISION, OCULAR; XENOBIOTICS;

EID: 84866494997     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.708337     Document Type: Review

References (153)

1. Brick DC. Medication errors result in costly claims for ophthalmologists. Surv Ophthalmol 1995;40(3):232-6
2. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: Recognition and management. Drugs 2007;67(1):75-93 (Pubitemid 46115915)
3. Moorthy RS, Valluri S. Ocular toxicity associated with systemic drug therapy. Curr Opin Ophthalmol 1999;10(6):438-46
4. Blomquist PH. Ocular complications of systemic medications. Am J Med Sci 2011;342(1):62-9
5. Garralda Luquin A. Ocular toxicity induced by medication. An Sist Sanit Navar 2008;31(Suppl 3):147-53
6. Hollander DA, Aldave AJ. Drug-induced corneal complications. Curr Opin Ophthalmol 2004;15(6):541-8 (Pubitemid 39564476)
7. Sodi A, Ioannidis A, Pitz S. Ophthalmological manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 26
8. Francois J. Cornea verticillata. Bull Soc Belge Ophtalmol 1968;150:656-70
9. Dua HS, Singh A, Gomes JA, et al. Vortex or whorl formation of cultured human corneal epithelial cells induced by magnetic fields. Eye (Lond) 1996;10(Pt 4):447-50 (Pubitemid 26285552)
10. D'Amico DJ, Kenyon KR. Drug-induced lipidoses of the cornea and conjunctiva. Int Ophthalmol 1981;4(1-2):67-76 (Pubitemid 11027370)
11. Ahn J, Wee WR, Lee JH, Hyon JY. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean J Ophthalmol 2011;25(5):355-7
12. Zhang G, Basti S, Jampol LM. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: Case reports and a review of literature. Cornea 2007;26(7):858-60 (Pubitemid 47220560)
13. Tullo AB, Esmaeli B, Murray PI, et al. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (Lond) 2005;19(7):729-38 (Pubitemid 41030567)
14. Yano S, Kondo K, Yamaguchi M, et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res 2003;23(5A):3639-50 (Pubitemid 37474306)
15. Yeh S, Fine HA, Smith JA. Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea 2009; 28(6):699-702
16. Salomao SR, Watanabe SE, Berezovsky A, Motono M. Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use. Curr Eye Res 2007;32(4):345-52 (Pubitemid 46633857)
17. Noureddin BN, Seoud M, Bashshur Z, et al. Ocular toxicity in low-dose tamoxifen: A prospective study. Eye (Lond) 1999;13(Pt 6):729-33 (Pubitemid 30050498)
18. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992;69(12):2961-4
19. Ingram DV, Jaggarao NS, Chamberlain DA. Ocular changes resulting from therapy with amiodarone. Br J Ophthalmol 1982;66(10):676-9 (Pubitemid 12018478)
20. Dolan BJ, Flach AJ, Peterson JS. Amiodarone keratopathy and lens opacities. J Am Optom Assoc 1985;56(6):468-70
21. Harris L, McKenna WJ, Rowland E, Krikler DM. Side effects and possible contraindications of amiodarone use. Am Heart J 1983;106(4 Pt 2):916-23 (Pubitemid 13010826)
22. Erdurmus M, Selcoki Y, Yagci R, Hepsen IF. Amiodarone-induced keratopathy: Full-thickness corneal involvement. Eye Contact Lens 2008;34(2):131-2 (Pubitemid 351355194)
23. Haug SJ, Friedman AH. Identification of amiodarone in corneal deposits. Am J Ophthalmol 1991;111(4):518-20
24. D'Amico DJ, Kenyon KR, Ruskin JN. Amiodarone keratopathy: Drug-induced lipid storage disease. Arch Ophthalmol 1981;99(2):257-61 (Pubitemid 11184137)
25. Wasielica-Poslednik J, Pfeiffer N, Reinke J, Pitz S. Confocal laser-scanning microscopy allows differentiation between Fabry disease and amiodarone-induced keratopathy. Graefes Arch Clin Exp Ophthalmol 2011;249(11):1689-96
26. Rivera RP, Younge BR, Dyer JA. Atypical amiodarone-induced keratopathy in a patient wearing soft contact lenses. CLAO J 1989;15(3):219-21 (Pubitemid 19201045)
27. Thystrup JD, Fledelius HC. Retinal maculopathy possibly associated with amiodarone medication. Acta Ophthalmol (Copenh) 1994;72(5):639-41 (Pubitemid 24370778)
28. Feiner LA, Younge BR, Kazmier FJ, et al. Optic neuropathy and amiodarone therapy. Mayo Clin Proc 1987;62(8):702-17 (Pubitemid 17118782)
29. Lochhead J, Salmon JF, Bron AJ. Cytarabine-induced corneal toxicity. Eye (Lond) 2003;17(5):677-8
30. Fintelmann RE, Qian Y, Skalet A, Jeng BH. Anterior uveitis associated with high-dose cytosine arabinoside. Ocul Immunol Inflamm 2010;18(6):485-7
31. Guthoff T, Tietze B, Meinhardt B, et al. Cytosine-arabinoside-induced keratopathy: A model of corneal proliferation kinetics. Ophthalmologica 2010;224(5):308-11
32. Hopen G, Mondino BJ, Johnson BL, Chervenick PA. Corneal toxicity with systemic cytarabine. Am J Ophthalmol 1981;91(4):500-4 (Pubitemid 11106424)
33. Lazarus HM, Hartnett ME, Reed MD, et al. Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabineinduced keratitis. Am J Ophthalmol 1987;104(5):476-80 (Pubitemid 17161699)
34. Kumar L, Dua H, Agarwal S, et al. Ocular toxicity of low dose cytosar. NZ Med J 1987;100(825):361
35. Lass JH, Lazarus HM, Reed MD, Herzig RH. Topical corticosteroid therapy for corneal toxicity from systemically administered cytarabine. Am J Ophthalmol 1982;94(5):617-21 (Pubitemid 13233950)
36. Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: A review. CNS Drugs 2010;24(6):501-26
37. Toshida H, Uesugi Y, Ebihara N, Murakami A. In vivo observations of a case of chlorpromazine deposits in the cornea using an HRT II Rostock corneal module. Cornea 2007;26(9):1141-3 (Pubitemid 47480705)
38. Fraunfelder FT, Fraunfelder FW, Edwards R. Ocular side effects possibly associated with isotretinoin usage. Am J Ophthalmol 2001;132(3):299-305 (Pubitemid 32768596)
39. Fraunfelder FT, LaBraico JM, Meyer SM. Adverse ocular reactions possibly associated with isotretinoin. Am J Ophthalmol 1985;100(4):534-7 (Pubitemid 16206982)
40. Rumsfield JA, West DP, Tse CS, et al. Isotretinoin in severe, recalcitrant cystic acne: A review. Drug Intell Clin Pharm 1983;17(5):329-33 (Pubitemid 13079713)
41. Labiris G, Katsanos A, Karapetsa M, et al. Association between isotretinoin use and central retinal vein occlusion in an adolescent with minor predisposition for thrombotic incidents: A case report. J Med Case Reports 2009;3:58
42. Ellies P, Dighiero P, Legeais JM, et al. Persistent corneal opacity after oral isotretinoin therapy for acne. Cornea 2000;19(2):238-9 (Pubitemid 30140830)
43. Kaur I, Ram J, Kumar B, et al. Effect of clofazimine on eye in multibacillary leprosy. Indian J Lepr 1990;62(1):87-90 (Pubitemid 20162361)
44. Craythorn JM, Swartz M, Creel DJ. Clofazimine-induced bull's-eye retinopathy. Retina 1986;6(1):50-2 (Pubitemid 16079226)
45. Ohman L, Wahlberg I. Letter: Ocular side-effects of clofazimine. Lancet 1975;2(7941):933-4
46. Walinder PE, Gip L, Stempa M. Corneal changes in patients treated with clofazimine. Br J Ophthalmol 1976;60(7):526-8
47. Font RL, Sobol W, Matoba A. Polychromatic corneal and conjunctival crystals secondary to clofazimine therapy in a leper. Ophthalmology 1989;96(3):311-15 (Pubitemid 19078902)
48. Barot RK, Viswanath V, Pattiwar MS, Torsekar RG. Crystalline deposition in the cornea and conjunctiva secondary to long-term clofazimine therapy in a leprosy patient. Indian J Ophthalmol 2011;59(4):328-9
49. Budde M, Gusek-Schneider GC, Mayer U, Seitz B. Annular crystalline keratopathy in association with immunoglobulin therapy for pyoderma gangrenosum. Cornea 2003;22(1):82-5 (Pubitemid 36076691)
50. Ormerod LD, Collin HB, Dohlman CH, et al. Paraproteinemic crystalline keratopathy. Ophthalmology 1988;95(2):202-12 (Pubitemid 18057875)
51. Osusky R, Morell A, Imbach P, Lerch PG. Diffusion of immunoglobulins into rabbit cornea after subconjunctival injection: Experimental demonstration and mathematical model. Graefes Arch Clin Exp Ophthalmol 1993; 231(2):122-8 (Pubitemid 23075148)
52. Koo H, Oh DH, Chun YS, Kim JC. A case of crystalline keratopathy in monoclonal gammopathy of undetermined significance (MGUS). Korean J Ophthalmol 2011;25(3):202-5
53. Lisch W, Saikia P. Immunotactoid microtubular corneal deposits in bilateral paraprotein crystalline keratopathy and atypical corneal immunoglobulin deposition in a patient with dysproteinemia. Cornea 2011; 30(2):247; author reply -8
54. Matoba AY, Chevez-Barrios P, Jones DB. Atypical corneal immunoglobulin deposition in a patient with dysproteinemia. Cornea 2010;29(1):105-7
55. Singh K. Immunotactoid microtubular corneal deposits in bilateral paraprotein crystalline keratopathy. Cornea 2009;28(7):829-31
56. McCormick SA, DiBartolomeo AG, Raju VK, Schwab IR. Ocular chrysiasis. Ophthalmology 1985;92(10):1432-5 (Pubitemid 16228037)
57. Bron AJ, McLendon BF, Camp AV. Epithelial deposition of gold in the cornea in patients receiving systemic therapy. Am J Ophthalmol 1979;88(3 Pt 1):354-60 (Pubitemid 9245050)
58. Hashimoto A, Maeda Y, Ito H, et al. Corneal chrysiasis. A clinical study in rheumatoid arthritis patients receiving gold therapy. Arthritis Rheum 1972;15(3):309-15
59. Paladini I, Menchini U, Mencucci R. Corneal chrysiasis: In vivo confocal microscopy analysis. Eur J Ophthalmol 2010;20(4):776-9
60. Lopez JD, del Castillo JM, Lopez CD, Sanchez JG. Confocal microscopy in ocular chrysiasis. Cornea 2003;22(6):573-5
61. Bhagat N, Read RW, Rao NA, et al. Rifabutin-associated hypopyon uveitis in human immunodeficiency virus-negative immunocompetent individuals. Ophthalmology 2001;108(4):750-2 (Pubitemid 32238471)
62. Schaller UC, Michl G, Goebel FD, Klauss V. Acute hypopyon uveitis with rifabutin therapy of systemic Mycobacterium avium complex (MAC) infection in AIDS. Ophthalmologe 1999;96(4):267-9 (Pubitemid 29202898)
63. Frau E, Gregoire-Cassoux N, Hannouche D, et al. Uveitis with hypopyon in patients with acquired immunodeficiency syndrome, treated with Rifabutin. J Fr Ophtalmol 1995;18 (6-7):435-8
64. Saran BR, Maguire AM, Nichols C, et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994;112(9):1159-65 (Pubitemid 24360953)
65. Arevalo JF, Freeman WR. Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Am J Ophthalmol 2000;129(3):410-11 (Pubitemid 30126105)
66. Holland SP, Chang CW, Vagh M, Courtright P. Corneal endothelial deposits in patients with HIV infection or AIDS: Epidemiologic evidence of the contribution of rifabutin. Can J Ophthalmol 1999;34(4):204-9
67. Ponjavic V, Granse L, Bengtsson Stigmar E, Andreasson S. Retinal dysfunction and anterior segment deposits in a patient treated with rifabutin. Acta Ophthalmol Scand 2002;80(5):553-6 (Pubitemid 35243865)
68. Smith JA, Mueller BU, Nussenblatt RB, Whitcup SM. Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia. Am J Ophthalmol 1999;127(2):164-9 (Pubitemid 29072556)
69. Nambiar S, Rellosa N, Wassel RT, et al. Linezolid-associated peripheral and optic neuropathy in children. Pediatrics 2011;127(6):e1528-382
70. Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006;66(4):595-8 (Pubitemid 43739898)
71. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf 2008;31(2):127-41 (Pubitemid 351158524)
72. Lee E, Burger S, Shah J, et al. Linezolid-associated toxic optic neuropathy: A report of 2 cases. Clin Infect Dis 2003;37(10):1389-91 (Pubitemid 37433638)
73. Le-Nguyen XT, Lee TK, Do DV, et al. Diagnostic and therapeutic challenges. Retina 2011;31(8):1732-9
74. Arnold AC. Ischemic optic neuropathies. Ophthalmol Clin North Am 2001;14(1):83-98 (Pubitemid 32381754)
75. Sharma P, Sharma R. Toxic optic neuropathy. Indian J Ophthalmol 2011;59(2):137-41
76. Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999;127(5):610-12 (Pubitemid 29215779)
77. Kokkada SB, Barthakur R, Natarajan M, et al. Ocular side effects of antitubercular drugs - a focus on prevention, early detection and management. Kathmandu Univ Med J (KUMJ) 2005;3(4):438-41
78. Vistamehr S, Walsh TJ, Adelman RA. Ethambutol neuroretinopathy. Semin Ophthalmol 2007;22(3):141-6 (Pubitemid 47346967)
79. Chai SJ, Foroozan R. Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. Br J Ophthalmol 2007;91(7):895-7 (Pubitemid 47013099)
80. Chan RY, Kwok AK. Ocular toxicity of ethambutol. Hong Kong Med J 2006;12(1):56-60 (Pubitemid 43287620)
81. Dillberger JE, Peiffer RL, Dykstra MJ, et al. The experimental antipsychotic agent 1192U90 targets tapetum lucidum in canine eyes. Toxicol Pathol 1996;24(5):595-601 (Pubitemid 26374764)
82. Vogel AW, Kaiser JA. Ethambutol-induced transient change and reconstitution (in Vivo) of the tapetum lucidum color in the dog. Exp Mol Pathol 1963;26:136-49
83. Kozak SF, Inderlied CB, Hsu HY, et al. The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy. Diagn Microbiol Infect Dis 1998;30(2):83-7
84. Lauer AK, Wobig JL, Shults WT, et al. Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy. Am J Ophthalmol 1999;127(2):230-3 (Pubitemid 29072578)
85. Ponjavic V, Granse L, Kjellstrom S, et al. Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin. Doc Ophthalmol 2004;108(2):125-33 (Pubitemid 39140120)
86. Nagaoka T, Sato E, Takahashi A, et al. Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci 2007;48(1):368-75 (Pubitemid 47251426)
87. Kadayifcilar S, Boyacioglu S, Kart H, et al. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye (Lond) 1999;13(Pt 2):241-6 (Pubitemid 29210148)
88. Engelke M, Tykhonova S, Zorn-Kruppa M, Diehl H. Tamoxifen induces changes in the lipid composition of the retinal pigment epithelium cell line D407. Pharmacol Toxicol 2002; 91(1):13-21 (Pubitemid 34753748)
89. Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 1994;117(6):772-5 (Pubitemid 24172030)
90. Toler SM. Oxidative stress plays an important role in the pathogenesis of drug-induced retinopathy. Exp Biol Med (Maywood) 2004;229(7):607-15 (Pubitemid 38878905)
91. Drenser K, Sarraf D, Jain A, Small KW. Crystalline retinopathies. Surv Ophthalmol 2006;51(6):535-49 (Pubitemid 44755288)
92. Parkkari M, Paakkala AM, Salminen L, Holli K. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: A randomized follow-up study. Acta Ophthalmol Scand 2003;81(5):495-9 (Pubitemid 37265670)
93. Ibanez HE, Williams DF, Boniuk I. Crystalline retinopathy associated with long-term nitrofurantoin therapy. Arch Ophthalmol 1994;112(3):304-5 (Pubitemid 24085135)
94. Kammire LD, Donofrio PD. Nitrofurantoin neuropathy: A forgotten adverse effect. Obstet Gynecol 2007;110(2 Pt 2):510-12 (Pubitemid 47417746)
95. Loo JL, Lee SY, Ang CL. Can long-term corticosteriods lead to blindness? A case series of central serous chorioretinopathy induced by corticosteroids. Ann Acad Med Singapore 2006;35(7):496-9
96. Kishi S, Yoshida O, Matsuoka R, Kojima Y. Serous retinal detachment in patients under systemic corticosteroid treatment. Jpn J Ophthalmol 2001;45(6):640-7 (Pubitemid 34081781)
97. Wegner A, Khoramnia R. Neurosensory retinal detachment due to sunitinib treatment. Eye (Lond) 2011;25(11):1517-18
98. Barot M, Gokulgandhi MR, Mitra AK. Mitochondrial dysfunction in retinal diseases. Curr Eye Res 2011;36(12):1069-77
99. Beyenburg S, Weyland C, Reuber M. Presumed topiramate-induced maculopathy. Epilepsy Behav 2009;14(3):556-9
100. Kjellstrom S, Bruun A, Isaksson B, et al. Retinal function and histopathology in rabbits treated with Topiramate. Doc Ophthalmol 2006;113(3):179-86 (Pubitemid 44835002)
101. Shinjo SK, Maia OO Jr, Tizziani VA, et al. Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: Related to disease duration? Clin Rheumatol 2007;26(8):1248-53 (Pubitemid 47034177)
102. Parthasarathi S, Myint K, Singh G, et al. Bilateral acetazolamide-induced choroidal effusion following cataract surgery. Eye (Lond) 2007;21(6):870-2 (Pubitemid 46909215)
103. Mahesh G, Giridhar A, Saikumar SJ, Fegde S. Drug-induced acute myopia following chlorthalidone treatment. Indian J Ophthalmol 2007;55(5):386-8
104. Schmid KE, Kornek GV, Scheithauer W, Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol 2006;51(1):19-40 (Pubitemid 43083371)
105. Hilliard LM, Berkow RL, Watterson J, et al. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol 1997;28(4):310-13 (Pubitemid 27123696)
106. Shingleton BJ, Bienfang DC, Albert DM, et al. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 1982;100(11):1766-72 (Pubitemid 12006665)
107. Boulton M, Rozanowska M, Rozanowski B. Retinal photodamage. J Photochem Photobiol B 2001;64(2-3):144-61 (Pubitemid 33133666)
108. Rozanowska M, Sarna T, Land EJ, Truscott TG. Free radical scavenging properties of melanin interaction of eu- and pheo-melanin models with reducing and oxidising radicals. Free Radic Biol Med 1999;26(5-6):518-25 (Pubitemid 29146254)
109. Mecklenburg L, Schraermeyer U. An overview on the toxic morphological changes in the retinal pigment epithelium after systemic compound administration. Toxicol Pathol 2007;35(2):252-67 (Pubitemid 46393071)
110. Leblanc B, Jezequel S, Davies T, et al. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol 1998;28(2):124-32 (Pubitemid 29076778)
111. Marmor MF, Carr RE, Easterbrook M, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the American Academy of Ophthalmology. Ophthalmology 2002;109(7):1377-82 (Pubitemid 34700934)
112. Eves P, Smith-Thomas L, Hedley S, et al. A comparative study of the effect of pigment on drug toxicity in human choroidal melanocytes and retinal pigment epithelial cells. Pigment Cell Res 1999;12(1):22-35 (Pubitemid 129685513)
113. Larsson BS. Interaction between chemicals and melanin. Pigment Cell Res 1993;6(3):127-33
114. Buszman E, Rozanska R. Interaction of thioridazine with ocular melanin in vitro. Acta Pol Pharm 2003;60(4):257-61 (Pubitemid 37279465)
115. To TQ, Townsend JC. Ocular toxicity of systemic medications: A case series. Optometry 2000;71(1):29-39
116. Brelsford M, Beute TC. Preventing and managing the side effects of isotretinoin. Semin Cutan Med Surg 2008;27(3):197-206
117. Santodomingo-Rubido J, Barrado-Navascues E, Rubido-Crespo MJ. Drug-induced ocular side-effects with isotretinoin. Ophthalmic Physiol Opt 2008;28(5):497-501
118. Choong YY, Lim KS. Phenothiazine deposits in corneo and lens. Med J Malaysia 2001;56(1):92-4 (Pubitemid 32786388)
119. Bratulescu M, Zemba M, Gheorghieva V, et al. Ocular manifestation in amiodarone toxicity--case report. Oftalmologia 2005;49(4):18-23
120. Chilov MN, Moshegov CN, Booth F. Unilateral amiodarone keratopathy. Clin Experiment Ophthalmol 2005;33(6):666-8
121. Domingues MF, Barros H, Falcao-Reis FM. Amiodarone and optic neuropathy. Acta Ophthalmol Scand 2004;82(3 Pt 1):277-82 (Pubitemid 38714643)
122. Honrubia A, Andres JM, Alcaine F, et al. Visual disorders induced by therapeutic levels of digoxin. Arch Soc Esp Oftalmol 2000;75(1):55-6
123. Hobley A, Lawrenson J. Ocular adverse effects to the therapeutic administration of digoxin. Ophthalmic Physiol Opt 1991;11(4):391-3
124. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 1997;56(3):188-90 (Pubitemid 27144204)
125. Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 1990;25(5):249-51 (Pubitemid 20289523)
126. Petrohelos MA. Chloroquine-induced ocular toxicity. Ann Ophthalmol 1974;6(6):615-18
127. Abtahi MA, Abtahi SH, Fazel F, et al. Topiramate and the vision: A systematic review. Clin Ophthalmol 2012;6:117-31
128. Pai K, Rajashekaran P. Glaucoma: Adverse event on use of topiramate in alcohol de-addiction. Indian J Psychiatry 2011;53(2):163-5
129. Jabbarpoor Bonyadi MH, Soheilian R, Soheilian M. Topiramate-induced bilateral anterior uveitis associated with hypopyon formation. Ocul Immunol Inflamm 2011;19(1):86-8
130. Hood CT, Langston RH, Schoenfield LR, Dupps WJ Jr. Amantadine-associated corneal edema treated with descemet's stripping automated endothelial keratoplasty. Ophthalmic Surg Lasers Imaging 2010; 41:1-4
131. Esquenazi S. Bilateral reversible corneal edema associated with amantadine use. J Ocul Pharmacol Ther 2009;25(6):567-70
132. Chang KC, Kim MK, Wee WR, Lee JH. Corneal endothelial dysfunction associated with amantadine toxicity. Cornea 2008;27(10):1182-5
133. Hughes B, Feiz V, Flynn SB, Brodsky MC. Reversible amantadine-induced corneal edema in an adolescent. Cornea 2004;23(8):823-4 (Pubitemid 39447314)
134. Fraunfelder FW, Solomon J, Mehelas TJ. Ocular adverse effects associated with cyclooxygenase-2 inhibitors. Arch Ophthalmol 2006;124(2):277-9 (Pubitemid 43247082)
135. Goldberg D, Panigrahi D, Barazi M, et al. A case of rofecoxib-associated stevens-johnson syndrome with corneal and conjunctival changes. Cornea 2004;23(7):736-7 (Pubitemid 39314789)
136. Ah-Song R, Sasco AJ. Tamoxifen and ocular toxicity. Cancer Detect Prev 1997;21(6):522-31 (Pubitemid 27518940)
137. Fraunfelder FW, Fraunfelder FT. Oculogyric crisis in patients taking cetirizine. Am J Ophthalmol 2004;137(2):355-7 (Pubitemid 38221016)
138. Sbeity ZH, Baydoun L, Schmidt S, Loeffler KU. Visual field changes in methotrexate therapy. Case report and review of the literature. J Med Liban 2006;54(3):164-7
139. Balachandran C, McCluskey PJ, Champion GD, Halmagyi GM. Methotrexate-induced optic neuropathy. Clin Experiment Ophthalmol 2002;30(6):440-1 (Pubitemid 36040412)
140. Harris A, Kagemann L, Ehrlich R, et al. The effect of sildenafil on ocular blood flow. Br J Ophthalmol 2008;92(4):469-73 (Pubitemid 351497970)
141. Su DH, Ang PS, Tow SL. Bilateral posterior ischemic optic neuropathy associated with use of sildenafil. J Neuroophthalmol 2008;28(1):75 (Pubitemid 351416898)
142. Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006;3(1):12-27
143. Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: Case report and review of the literature. Graefes Arch Clin Exp Ophthalmol 2010;248(2):283-7
144. Mumoli N, Niccoli G, Scazzeri F, et al. Infliximab-induced retrobulbar optic neuritis. QJM 2007;100(8):531 (Pubitemid 47241920)
145. McKague M, Jorgenson D, Buxton KA. Ocular side effects of bisphosphonates: A case report and literature review. Can Fam Physician 2010;56(10):1015-17
146. Papapetrou PD. Bisphosphonate-associated adverse events. Hormones (Athens) 2009;8(2):96-110
147. Leung S, Ashar BH, Miller RG. Bisphosphonate-associated scleritis: A case report and review. South Med J 2005;98(7):733-5 (Pubitemid 41061662)
148. Stewart O, Chang B, Bradbury J. Simultaneous administration of hepatitis B and polio vaccines associated with bilateral optic neuritis. Br J Ophthalmol 1999;83(10):1200-1 (Pubitemid 29469136)
149. van de Geijn EJ, Tukkie R, van Philips LA, Punt H. Bilateral optic neuritis with branch retinal artery occlusion associated with vaccination. Doc Ophthalmol 1994;86(4):403-8 (Pubitemid 24322985)
150. Kulkarni HS, Keskar VS, Bavdekar SB, Gabhale Y. Bilateral optic neuritis due to isoniazid (INH). Indian Pediatr 2010; 47(6):533-5
151. Whitcup SM, Butler KM, Caruso R, et al. Retinal toxicity in human immunodeficiency virus-infected children treated with 2',3'-dideoxyinosine. Am J Ophthalmol 1992;113(1):1-7
152. Meyer CH, Schmidt JC, Rodrigues EB, Mennel S. Risk of retinal vein occlusions in patients treated with rofecoxib (vioxx). Ophthalmologica 2005;219(4):243-7 (Pubitemid 41160195)
153. Rapp P, Pilon F, Chiambaretta F, et al. Bilateral uveitis with definitive hypotony caused by systemic cidofovir. J Fr Ophtalmol 2003;26(7):717-19 (Pubitemid 37169061)